Expert consensus on liquid biopsy-based multi-cancer early detection (2025 edition)
10.3760/cma.j.cn112152-20250605-00257
- VernacularTitle:基于液体活检技术的多癌种联合筛查专家共识（2025版）
- Author:
Wanqing CHEN
1
;
Kexin CHEN
;
Yutong HE
;
Weihua JIA
;
Zhihua LIU
;
Hongxia MA
;
Xiaoping MIAO
;
Kaifeng PAN
;
Chen WU
;
Changfa XIA
;
Jinliang XING
;
Yongjie XU
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院癌症早诊早治办公室，北京 100021
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Liquid biopsy;
Multi-cancer early detection;
Tumor biomarkers;
Expert consensus
- From:
Chinese Journal of Oncology
2025;47(7):558-574
- CountryChina
- Language:Chinese
-
Abstract:
Cancer stands as a significant global public health challenge, and cancer screening serves as a pivotal strategy for reducing its mortality. Presently, only a limited number of cancer types have appropriate screening methods available. Traditional single-cancer screening approaches are fraught with limitations, including invasiveness, low accuracy, and poor patient compliance. Multi-cancer early detection (MCED) leveraging liquid biopsy technology enables non-invasive and efficient early detection of multiple cancers by analyzing biomarkers such as cell-free DNA, cell-free RNA, proteins, and metabolites in blood and other bodily fluids. This innovative approach substantially broadens the spectrum of detectable cancers and enhances population coverage, showcasing immense potential for improving existing cancer screening strategies. This expert consensus comprehensively reviews the progress of liquid biopsy-based MCED, biomarker selection and detection technologies, the criteria for cancer type selection, research design and clinical utility evaluation, as well as implementation pathways. The overarching goal of this consensus is to offer scientific guidance for further research and the widespread adoption of MCED, thereby facilitating the continuous optimization of cancer screening strategies.
